Dual-Checkpoint Immunotherapy Combined With First-Line Treatment
Instead of blocking only one immune pathway, cadonilimab is designed to enhance immune activity through two complementary mechanisms.
For patients with persistent, recurrent or metastatic cervical cancer, cadonilimab can be combined with platinum-based chemotherapy. Bevacizumab, an anti-angiogenic therapy, may also be added when clinically appropriate.
The treatment concept therefore combines:
Cadonilimab + platinum-based chemotherapy ± bevacizumab
This strategy was evaluated in the phase III COMPASSION-16 study involving previously untreated patients with persistent, recurrent or metastatic cervical cancer.
Median progression-free survival was 12.7 months in the cadonilimab combination group versus 8.1 months with standard treatment alone. The study also demonstrated an improvement in overall survival, with the risk of death reduced compared with the control group.
Later subgroup analysis showed that the progression-free and overall survival benefit was generally maintained across a range of patient groups, including differences in PD-L1 status, previous chemoradiotherapy and use or non-use of bevacizumab.
This is clinically important because recurrent or metastatic cervical cancer can be difficult to control once it is no longer suitable for curative surgery or radiotherapy.
The combination attempts to attack cancer in several ways simultaneously: chemotherapy directly damages rapidly dividing cancer cells; cadonilimab helps restore immune responses; and bevacizumab, when used, limits VEGF-driven tumor blood-vessel development.
Patients who may be evaluated for this treatment include those with:
- Persistent cervical cancer after previous local therapy
- Recurrent cervical cancer
- Metastatic cervical cancer
- No previous systemic treatment for recurrent or metastatic disease
- Adequate bone marrow, liver and kidney function
Because both chemotherapy and immune therapy can produce significant adverse effects, treatment should be delivered with regular blood tests, imaging and monitoring for immune-related complications.
For suitable patients, this combination offers a modern first-line strategy that moves beyond chemotherapy alone by integrating dual-checkpoint immunotherapy into the treatment plan.
